X4 Pharmaceuticals, Inc (XFOR)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 10M 20M 30M Q3 '20: 0 Q4 '20: 0 Q1 '21: 0 Q2 '21: 0 Q3 '21: 0 Q4 '21: 0 Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q1 '24: 0 Q2 '24: 563K Q3 '24: 560K Q4 '24: 1.4M Q1 '25: 28.8M Q2 '25: 2M Q3 '25: 1.8M Q4 '25: 2.6M Q1 '26: 2.7M Q2 '26: 8.8M Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 9M 18M 27M Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q1 '24: 0 Q2 '24: 295K Q3 '24: 333K Q4 '24: 1.1M Q1 '25: 24.1M Q2 '25: 1.6M Q3 '25: 1.4M Q4 '25: 2.2M Q1 '26: 2.1M Q2 '26: 7.2M Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-50M -25M 0 25M 50M 75M Q3 '21: -19.1M Q4 '21: -29.1M Q1 '22: -21.3M Q2 '22: -20.6M Q3 '22: -20.2M Q4 '22: -25.6M Q1 '23: -29.3M Q2 '23: -25.8M Q3 '23: -27.2M Q4 '23: -25.2M Q1 '24: -37.3M Q2 '24: 71.1M Q3 '24: -34.5M Q4 '24: -35.7M Q1 '25: -9.4M Q2 '25: -26.2M Q3 '25: -27.5M Q4 '25: -23.7M Q1 '26: -20.3M Q2 '26: -16.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-70M -35M 0 35M 70M 105M Q3 '21: -20.2M Q4 '21: -30.2M Q1 '22: -22M Q2 '22: -21.2M Q3 '22: -21.6M Q4 '22: -29.1M Q1 '23: -24M Q2 '23: -55.7M Q3 '23: -2.3M Q4 '23: -19.1M Q1 '24: -51.8M Q2 '24: 90.8M Q3 '24: -36.7M Q4 '24: -39.8M Q1 '25: 282K Q2 '25: -25.7M Q3 '25: -29.8M Q4 '25: -23.9M Q1 '26: -20.2M Q2 '26: -16.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 2M 4M 6M Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q1 '24: 0 Q2 '24: 268K Q3 '24: 227K Q4 '24: 302K Q1 '25: 4.7M Q2 '25: 326K Q3 '25: 351K Q4 '25: 364K Q1 '26: 598K Q2 '26: 1.6M Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '21: -14.2M Q4 '21: -19.1M Q1 '22: -20.2M Q2 '22: -18.5M Q3 '22: -19.3M Q4 '22: -19.1M Q1 '23: -26.5M Q2 '23: -47.9M Q3 '23: -68.8M Q4 '23: -27.7M Q1 '24: -33.6M Q2 '24: -63.9M Q3 '24: -34M Q4 '24: -33M Q1 '25: -12.4M Q2 '25: -29.9M Q3 '25: -27.8M Q4 '25: -15.5M Q1 '26: -19.6M Q2 '26: -20.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q1 '21: -18.9M Q2 '21: -19.3M Q3 '21: -14.2M Q4 '21: -19.1M Q1 '22: -20.3M Q2 '22: -18.5M Q3 '22: -19.3M Q4 '22: -19.1M Q1 '23: -26.5M Q2 '23: -47.9M Q3 '23: -68.8M Q4 '23: -27.8M Q1 '24: -33.7M Q2 '24: -64M Q3 '24: -34.1M Q4 '24: -33M Q1 '25: -12.4M Q2 '25: -29.9M Q3 '25: -27.8M Q4 '25: -15.5M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q3 '21: 26.6M Q1 '22: 33.7M Q2 '22: 35.4M Q3 '22: 83.2M Q1 '23: 146M Q2 '23: 168.7M Q3 '23: 197M Q1 '24: 6.7M Q2 '24: 6.7M Q3 '24: 6.7M Q1 '25: 6.9M Q2 '25: 7.4M Q3 '25: 43.3M Q1 '26: 126.3M Q2 '26: 126.3M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-27.00 -18.00 -9.00 0.00 9.00 18.00 27.00 Q3 '21: -3.71 Q4 '21: -4.08 Q1 '22: -3.50 Q2 '22: -3.36 Q3 '22: -2.86 Q4 '22: -1.78 Q1 '23: -1.22 Q2 '23: -0.95 Q3 '23: -0.70 Q4 '23: -17.09 Q1 '24: -24.70 Q2 '24: -10.80 Q3 '24: -16.27 Q4 '24: -5.59 Q1 '25: 2.22 Q2 '25: -14.82 Q3 '25: -10.03 Q4 '25: -1.87 Q1 '26: -2.07 Q2 '26: 1.27 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.